Zhi Shang

机构：Shanghai Medical College of Fudan University, Peking University, Fudan University Shanghai Cancer Center, Shanghai Cancer Institute, Peking University Third Hospital · ORCID：0000-0002-1413-0039

发表论文 93 篇 · 总被引 1010 次 · h-index 20

代表论文

• Association between triglyceride-glucose index and risk of end-stage renal disease in patients with type 2 diabetes mellitus and chronic kidney disease (2023 · Frontiers in Endocrinology · 被引 42)
• Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways (2024 · Journal of Ethnopharmacology · 被引 33)
• Shenge Formula attenuates high-fat diet-induced obesity and fatty liver via inhibiting ACOX1 (2023 · Phytomedicine · 被引 31)
• Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study (2023 · Journal of Immunotherapy · 被引 25)
• Electroacupuncture Pretreatment at Zusanli (ST36) Ameliorates Hepatic Ischemia/Reperfusion Injury in Mice by Reducing Oxidative Stress via Activating Vagus Nerve-Dependent Nrf2 Pathway (2023 · Journal of Inflammation Research · 被引 22)
• Exploring the Therapeutic Potential of TGF-β Inhibitors for Liver Fibrosis: Targeting Multiple Signaling Pathways (2025 · Journal of Clinical and Translational Hepatology · 被引 16)